Skip to main content
. 2015 Jul 7;6(28):24823–24841. doi: 10.18632/oncotarget.4485

Figure 1. Vemurafenib and/or Trametinib treatments induce selective ErbB3 phosporylation and AKT activation in melanoma cells.

Figure 1

A375, M229 and WM115 cells were serum starved for 24 h, treated or not with vemurafenib (0.3 μM), with trametinib (0.15 μM) or with their combination for 24 h. Western blot analysis performed using the indicated antibodies shows that both vemurafenib and trametinib induce a strong phosphorylation of ErbB3 (Y1289) and AKT (S473). For densitometric analysis results are expressed as mean values from three independent experiments.